Document Detail

Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy.
MedLine Citation:
PMID:  23205518     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Pregabalin , the S-enantiomer of 3-aminomethyl-5-methylhaxanoic acid, is a second-generation antiepileptic drug (AED) developed after gabapentin with improved pharmacokinetic and pharmacodynamics properties. Pregabalin has a linear uptake without transporter saturation at therapeutic dosages, high bioavailability with rapid absorption independent of food intake. There is no binding to plasma proteins, and more than 90% of the drug is renally excreted, mostly without prior metabolization. Binding to the α(2)δ subunit of P/Q-type voltage-gated calcium channels, pregabalin is thought to exert its antiepileptic potency by modulating calcium channel traffic and physiology thus reducing the presynaptic calcium influx and subsequent neurotransmitter release.
AREAS COVERED: The article presents the pharmacokinetics and pharmacodynamics of pregabalin as well as its efficacy and tolerability in clinical trials. The article also looks at its clinical application as a combination therapy with particular respect to its pharmacokinetic profile.
EXPERT OPINION: The higher intrinsic potency of pregabalin compared to gabapentin is associated with an increased antiepileptic efficacy both in animal models of epilepsy and in clinical applications. In randomized add-on trials, seizure reduction compares favorably with other second-generation AED. Reliable absorption, absence of protein binding and hepatic metabolism make treatment reliable as does the absence of interactions with coadministered drugs. The rapid onset of action with significant antiepileptic effects at dosages of 150 - 600 mg/day makes pregabalin an option in patients with high seizure frequency. Whereas weight gain in some patients can cause acceptance problems, favorable effects on mood offer advantages in many patients with chronic epilepsy and psychiatric comorbidities.
Andreas Schulze-Bonhage
Related Documents :
2874568 - The effects of cysteamine on dopamine-mediated behaviors: evidence for dopamine-somatos...
23237348 - Treatment of myoclonic seizures.
21231888 - Development of amitriptyline buccoadhesive tablets for management of pain in dental pro...
7291998 - Persistent behavior at high rates maintained by intravenous self-administration of nico...
22161308 - Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as in...
1965908 - The use of rat leydig tumor (r2c) and human hepatoma (hepg2) cells to evaluate potentia...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-12-04
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  9     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-17     Completed Date:  2013-10-17     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  105-15     Citation Subset:  IM    
University Hospital of Freiburg, Freiburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / pharmacokinetics*,  pharmacology*,  therapeutic use
Epilepsy / drug therapy*,  metabolism*
Randomized Controlled Trials as Topic / trends
Treatment Outcome
gamma-Aminobutyric Acid / analogs & derivatives*,  pharmacokinetics,  physiology,  therapeutic use
Reg. No./Substance:
0/Anticonvulsants; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  O,O'-Diester methylenediphosphonotetrathioate-Synthesis, Characterization, and Potential Application...
Next Document:  Formation of a stable mimic of ambient particulate matter containing viable infectious Respiratory S...